Curcuma longa has long history of medicinal use in Ayurveda. A unique product NR-INF-02 was prepared from C. longa that was standardized to contain turmerosaccharides.
The present study investigated the effect of turmerosaccharides rich fraction of NR-INF-02 on monosodium iodoacetate (MIA)-induced OA pain animal model that mimics human OA. Further, the analgesic effect of turmerosaccharides rich fraction was compared to turmerosaccharides less fraction of NR-INF-02.
Materials and Methods:
OA pain was chemically induced by intra-articular administration of single dose of 25 μl of 0.9% saline containing 0.3 mg MIA into the right knee of male albino Wistar rat. Turmerosaccharides rich fraction and turmerosaccharides less fraction (at 22.5, 45 and 90 mg/kg rat body weight dose levels) were administered as a single dose orally on day 5 of post-MIA injection. OA pain was measured using hind limb weight-bearing ability at 1, 3, 6, and 24 h post-test substance administration on day 5.
Oral administration of turmerosaccharides rich fraction and turmerosaccharides less fraction (at 45 and 90 mg/kg) although significantly decreased the OA pain at all the intervals, the effect of turmerosaccharides rich fraction (57%) on OA pain was superior to turmerosaccharides less fraction (35%).
Bioactive turmerosaccharides from C. longa extract contribute to the observed anti-arthritic effect in rats.
- Osteoarthritic pain was induced by intra-articular injection of MIA into the right knee
- Single administration of TRF/TLF on day 5 resulted in dose-dependent significant reduction of OA pain
- TRF showed better analgesic activity than TLF
- TRF at 45 and 90 mg/kg has similar effects on OA pain as that of tramadol
- Turmerosaccharides identified as bioactive constituents of C. longa extract.
Read the full article here: